D. Fyfe

2.5k total citations · 2 hit papers
14 papers, 1.4k citations indexed

About

D. Fyfe is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D. Fyfe has authored 14 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D. Fyfe's work include Esophageal Cancer Research and Treatment (4 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Treatment and Pharmacology (4 papers). D. Fyfe is often cited by papers focused on Esophageal Cancer Research and Treatment (4 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Treatment and Pharmacology (4 papers). D. Fyfe collaborates with scholars based in United Kingdom, United States and Australia. D. Fyfe's co-authors include D. Ferry, Rachel Kerr, David A. Anderson, Adam J. de Smith, J Baker, Eric Gardiner, F. Lofts, Joseph Sgouros, Anthony Maraveyas and Wasat Mansoor and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

D. Fyfe

14 papers receiving 1.4k citations

Hit Papers

Phase I clinical trial of the flavonoid quercetin: pharma... 1996 2026 2006 2016 1996 2013 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
    1996 536 citations D. Ferry, Adam J. de Smith et al. PubMed profile →
  2. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    2013 405 citations Hugo Ford, Andrea Marshall et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Fyfe United Kingdom 11 463 436 309 283 234 14 1.4k
Ophelia Yin United States 28 647 1.4× 199 0.5× 433 1.4× 138 0.5× 104 0.4× 94 2.3k
Nir I. Weijl Netherlands 16 418 0.9× 244 0.6× 291 0.9× 124 0.4× 78 0.3× 22 1.4k
Stefania Grimaudo Italy 36 328 0.7× 70 0.2× 1.0k 3.2× 315 1.1× 117 0.5× 136 4.2k
Theunis C. Goosen United States 30 1.2k 2.6× 133 0.3× 756 2.4× 156 0.6× 107 0.5× 62 3.0k
Bruno Reigner Switzerland 27 2.1k 4.6× 611 1.4× 352 1.1× 352 1.2× 17 0.1× 66 3.3k
Kazuya Nakagawa Japan 17 322 0.7× 102 0.2× 226 0.7× 217 0.8× 31 0.1× 74 994
EJ Lee United States 20 380 0.8× 76 0.2× 388 1.3× 142 0.5× 9 0.0× 82 2.0k
Sooyoung Shin South Korea 16 119 0.3× 150 0.3× 223 0.7× 134 0.5× 15 0.1× 58 947
Robert M. Knabb United States 36 317 0.7× 101 0.2× 751 2.4× 331 1.2× 1.0k 4.4× 98 4.3k
Hideo Hakusui Japan 19 574 1.2× 58 0.1× 581 1.9× 143 0.5× 21 0.1× 88 1.6k

Countries citing papers authored by D. Fyfe

Since Specialization
Citations

This map shows the geographic impact of D. Fyfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Fyfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Fyfe more than expected).

Fields of papers citing papers by D. Fyfe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Fyfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Fyfe. The network helps show where D. Fyfe may publish in the future.

Co-authorship network of co-authors of D. Fyfe

This figure shows the co-authorship network connecting the top 25 collaborators of D. Fyfe. A scholar is included among the top collaborators of D. Fyfe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Fyfe. D. Fyfe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Petty, Russell, Åsa Dahle-Smith, Zosia Miedzybrodzka, et al.. (2014). Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).. Journal of Clinical Oncology. 32(15_suppl). 4016–4016. 14 indexed citations
2.
Ford, Hugo, Andrea Marshall, John Bridgewater, et al.. (2013). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet Oncology. 15(1). 78–86. 405 indexed citations breakdown →
3.
4.
5.
Maraveyas, Anthony, Justin S. Waters, Rajarshi Roy, et al.. (2011). Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer. 48(9). 1283–1292. 234 indexed citations
6.
7.
Maraveyas, Anthony, D. Fyfe, F. Lofts, et al.. (2009). 6503 Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). European Journal of Cancer Supplements. 7(2). 362–362. 28 indexed citations
8.
Plummer, Ruth, Penella J. Woll, D. Fyfe, et al.. (2008). A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14(24). 8288–8294. 12 indexed citations
9.
Cox, Karen, Eleanor Wilson, Laura Jones, & D. Fyfe. (2007). An exploratory, interview study of oncology patients' and health‐care staff experiences of discussing resuscitation. Psycho-Oncology. 16(11). 985–993. 16 indexed citations
10.
Khan, Sarah, A.S. Dhadda, D. Fyfe, & Santhanam Sundar. (2007). Impact of neutropenia on delivering planned chemotherapy for solid tumours. European Journal of Cancer Care. 0(0). 2730512449–???. 29 indexed citations
11.
Fyfe, D., Clare F. Price, Ruth E. Langley, et al.. (2001). A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemotherapy and Pharmacology. 47(4). 333–337. 10 indexed citations
12.
Fyfe, D., Florence I. Raynaud, Ruth E. Langley, et al.. (2001). A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. Cancer Chemotherapy and Pharmacology. 49(1). 1–6. 2 indexed citations
13.
Christodoulou, Constantina, D. Ferry, D. Fyfe, et al.. (1998). Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.. Journal of Clinical Oncology. 16(8). 2761–2769. 94 indexed citations
14.
Ferry, D., Adam J. de Smith, D. Fyfe, et al.. (1996). Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.. PubMed. 2(4). 659–68. 536 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ophelia Yin Breakdown of academic impact, for papers by Nir I. Weijl Breakdown of academic impact, for papers by Stefania Grimaudo Breakdown of academic impact, for papers by Theunis C. Goosen Breakdown of academic impact, for papers by Bruno Reigner Breakdown of academic impact, for papers by Kazuya Nakagawa Breakdown of academic impact, for papers by EJ Lee Breakdown of academic impact, for papers by Sooyoung Shin Breakdown of academic impact, for papers by Robert M. Knabb Breakdown of academic impact, for papers by Hideo Hakusui
Rankless by CCL
2026